The Food and Drug Administration is granting approval for a pill that could make treating hepatitis C more convenient and effective.

Its called Sovaldi and it could become one of the top-selling drugs worldwide.

The pill would allow some hepatitis C patients to avoid getting weekly injections of a medication that can cause serious side effects.

Sovaldi's cure rate exceeds 80 percent.

The downside is 12 weeks of treatment with the daily pill would cost about $84,000.